Clopidogrel, Poor Metabolism of, Ischemic Stroke
Conditions
Brief summary
Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.
Interventions
DIAGNOSTIC_TESTQuantification of platelet aggregation
Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
Sponsors
Ziv Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ability to provide written informed consent and to be compliant with protocol assessments. 2. Ages 18 and above inclusive 3. Both genders eligible for the study 4. Diagnosis of ischemic cerebrovascular event
Exclusion criteria
1. Pregnant patients will be excluded 2. Ages below 18 3. Patients not able to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rates of clopidogrel resistance assessed among the different ethnicities | 6 months |
| Identifying of high-risk subgroups of adverse clinical outcomes | 6 to 12 months |
Outcome results
None listed